profit from every $100 of sales.
$0$100
Pediatrix Medical Group
$31.30-0.32% today
+38.3% in 1 year
1-year low $18.821-year high $32.80
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $14.79 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Pediatrix Medical Group sold, what it kept, and what it did with the cash.
Sales went from $1.97 billion in 2022 to $1.91 billion in 2025, with $165 million of profit last year.
SalesProfit
Pediatrix Medical Group handed back 34% of the cash it generated last year.
Buybacks $87M
Free cash flow 2025$253M
Bought back its own shares$87M
Paid as dividends–
Cash vs. debt$375M vs. $635M
Pediatrix Medical Group vs. similar companies
Pediatrix Medical Group grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pediatrix Medical Group | 14.8× · Cheap | ||
 Tenet Healthcare | 16.2× · Fair price | ||
 Solventum | 9.7× · Cheap | ||
 Encompass Health | 24.4× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.6× · Cheap |
AI analysis
An AI analyst reads Pediatrix Medical Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,972 | 1,995 | 2,013 | 1,914 | |
| 467 | 422 | 454 | 494 | |
| 200 | 158 | 184 | 231 | |
| 157 | 30 | -28 | 274 | |
| 66 | -60 | -99 | 165 | |
| 0.79 | -0.73 | -1.19 | 1.94 | |
| 23.7% | 21.1% | 22.6% | 25.8% | |
| 10.1% | 7.9% | 9.1% | 12.1% | |
| 3.4% | -3.0% | -4.9% | 8.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,348 | 2,220 | 2,153 | 2,247 |
| Cash | 10 | 73 | 230 | 375 |
| Total debt | 717 | 702 | 662 | 635 |
| Total liabilities | 1,456 | 1,371 | 1,388 | 1,381 |
| 892 | 849 | 765 | 866 | |
| 84 | 84 | 86 | 85 | |
| 5.9% | -0.3% | -3.4% | 13.3% | |
| 7.4% | -7.1% | -13.0% | 19.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 167 | 137 | 207 | 271 | |
| 30 | 33 | 22 | 18 | |
| 137 | 104 | 185 | 253 | |
| Dividends paid | – | – | – | – |
| 89 | 1 | 2 | 87 | |
| 16 | 12 | 12 | 18 |
Valuation
- 14.8×
- 14.0×
- 0.42
- 2.0×
- 1.3×
- 9.7×
- 9.9×
- 10.3%
- 6.8%
- 0.0%
Profitability
- 25.8%
- 12.1%
- 8.6%
- 14.4%
- 9.6%
- 2.2%
- 20.1%
- 8.4%
- 14.1%
- –
Growth
- −1.0%
- +34.9%
- +36.9%
- –
- −0.3%
Financial health
- 1.5×
- 0.72
- 30.4%
- 7.9×
- 1.33
- 1.33
- 0.93
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 33%of 964
Top 47%of 898
Top 20%of 651
Bottom 15%of 911
Top 8%of 991
What analysts expect
- Average price target
- $22.25
- Range
- $19.00 – $27.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.44 | 0.37 | +18.9% |
| Feb 19, 2026 | 0.50 | 0.53 | −5.7% |
| Nov 3, 2025 | 0.67 | 0.46 | +45.7% |
| Aug 5, 2025 | 0.53 | 0.42 | +26.2% |
| May 6, 2025 | 0.33 | 0.25 | +32.0% |
| Feb 20, 2025 | 0.51 | 0.37 | +37.8% |
| Nov 1, 2024 | 0.44 | 0.37 | +18.9% |
| Aug 6, 2024 | 0.34 | 0.31 | +9.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
49No pass
Philip Fisher
56No pass
Peter Lynch
78Pass
Joel Greenblatt
44No pass
Charlie Munger
39No pass
Terry Smith
40No pass
Questions about Pediatrix Medical Group
Is Pediatrix Medical Group a good stock to buy?
A solid business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pediatrix Medical Group AI analysis
What does Pediatrix Medical Group do?
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It is in Medical - Care Facilities.
Does Pediatrix Medical Group pay a dividend?
No. Pediatrix Medical Group does not pay a dividend at the moment; in 2025 it returned $86.7 million to shareholders by buying back its own shares.
Is Pediatrix Medical Group stock halal?
Yes. Pediatrix Medical Group passes our halal screen: its business is permitted and its debt is 26% of its market value, under the 30% limit. How we check
How has Pediatrix Medical Group stock done over the past year?
Up 38.3% over the past twelve months, to $31.30. It traded between $18.82 and $32.80 and is 4.6% below its high.
Who are Pediatrix Medical Group's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with Pediatrix Medical Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.